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ABSTRACT 48 
Background: Glucagon-like peptide 1 agonists differ in chemical structure, duration of 49 
action and in their effects on clinical outcomes. The cardiovascular effects of once-weekly 50 
albiglutide in type 2 diabetes are unknown.   51 
  52 
Methods: We randomly assigned patients with type 2 diabetes and cardiovascular disease to 53 
the addition of once-weekly subcutaneous injection of albiglutide (30 mg to 50 mg) or 54 
matching placebo to standard care. We hypothesized that albiglutide would be noninferior to 55 
placebo for the primary outcome of first occurrence of cardiovascular death, myocardial 56 
infarction, or stroke. If noninferiority was confirmed by an upper limit of the 95% confidence 57 
interval for the hazard ratio of less than 1.30, closed-testing for superiority was prespecified. 58 
 59 
Findings: Overall, 9463 participants were followed for a median of 1.6 years. The primary 60 
composite outcome occurred in 338 of 4731 patients (7.1%; 4.6 events per 100 person-years) 61 
in the albiglutide group and in 428 of 4732 patients (9.0%; 5.9 events per 100 person-years) 62 
in the placebo group (hazard ratio, 0.78; 95% confidence interval [CI ], 0.68 to 0.90), 63 
indicating that albiglutide, was superior to placebo (P<0.0001 for noninferiority, P=0.0006 64 
for superiority).  65 
The incidence of acute pancreatitis (albiglutide 10 patients and placebo 7 patients), pancreatic 66 
cancer (6 and 5), medullary thyroid carcinoma (0 and 0), and other serious adverse events did 67 
not differ significantly between the two groups. 68 
 69 
Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior 70 
to placebo with respect to major adverse cardiovascular events.  71 
(Funded by GlaxoSmithKline; Harmony Outcomes ClinicalTrials.gov number, NCT02465515.) 72 
 73 
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Research in context 96 
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Evidence before this study 98 
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We searched PubMed for reports of randomised trials assessing the effects of glucagon-like 99 
peptide 1 agonists on cardiovascular outcomes published in English up to August 1, 2018, 100 
using the search terms “glucagon-like peptide 1 agonist or analogue”, “GLP-1 receptor 101 
agonist or analogue”, “exenatide”, “lixisenatide”, “semaglutide”, “liraglutide”, “exenatide”, 102 
“dulaglutide”, “taspoglutide”, “albiglutide”, “cardiovascular outcomes”, and “diabetes”. Four 103 
cardiovascular outcome trials were identified. The LEADER trial included 9340 patients with 104 
type 2 diabetes and cardiovascular disease or cardiovascular risk factors which were followed 105 
for a median of 3.8 years. Patients were randomised to placebo or once-daily liraglutide, 106 
structurally homologous to native GLP-1, added to standard care. Liraglutide reduced the 107 
primary endpoint composite of major adverse cardiovascular events (MACE) consisting of 108 
cardiovascular death, myocardial infraction or stroke (hazard ratio [HR], 0.87; 95% 109 
confidence interval [CI], 0.78 to 0.97; P<0.001 for noninferiority; P = 0.01 for superiority). 110 
Semaglutide, also structurally homologous to native GLP-1, was studied in 3297 similar 111 
participants in the SUSTAIN-6 trial which showed that, over a median of 2.1 years, once-112 
weekly semaglutide was noninferior to placebo for MACE (HR, 0.74; 95%CI, 0.58 to 0.95; 113 
P<0.001 for noninferiority). The ELIXA trial included 6068 patients with type 2 diabetes and 114 
a recent acute coronary syndrome which were followed for a median of 2.1 years. Patients 115 
were randomised to placebo or lixisenatide once daily, an exendin-4 based GLP-1 receptor 116 
agonist, added to standard care. Lixisenatide was non-inferior to placebo for the primary 117 
composite outcome of MACE plus unstable angina (HR, 1.02; 95%CI, 0.89 to 1.17; P<0.001 118 
for noninferiority). The EXSCEL trial included 14,752 patients with type 2 diabetes and 119 
cardiovascular disease or cardiovascular risk factors which were followed for a median of 3.2 120 
years. Patients were randomised to placebo or exenatide once weekly, an exendin-4 based 121 
GLP-1 receptor agonist, added to standard care. Exenatide was non-inferior to placebo for the 122 
primary composite outcome of MACE (HR, 0.91; 95%CI, 0.83 to 1.00; P<0.001 for 123 
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noninferiority; P = 0.06 for superiority). There seems to be variation in the results of existing 124 
trials with GLP-1 receptor agonists, which if correct, might reflect drug structure or duration 125 
of action, patients studied, duration of follow-up or other factors. 126 
Added value of this study 127 
The results of the Harmony Outcomes trial showed that albiglutide, the GLP-1 receptor 128 
ligand of which is structurally homologous with native GLP-1, administered once-weekly 129 
over a median period of 1.6 years, reduced the risk of MACE when added to standard care in 130 
patients with type 2 diabetes and cardiovascular disease.  The totality of evidence suggests 131 
that GLP-1 receptor agonists reduce the risk of athero-thrombotic events in patients with type 132 
2 diabetes and high cardiovascular risk.  133 
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INTRODUCTION 134 
The risk of fatal and nonfatal cardiovascular events is much higher in people with type 2 135 
diabetes than in the general population.1,2  Agents in two classes of newer glucose-lowering 136 
therapies, the sodium-glucose cotransporter 2 (SGLT-2) inhibitors and the glucagon-like 137 
peptide-1 (GLP-1) receptor agonists, have been shown to reduce the risk of major adverse 138 
cardiovascular events, although the findings with the latter treatments have been 139 
inconsistent.3-8  Specifically, not all tested GLP-1 receptor agonists reduced cardiovascular 140 
events and the effect on individual cardiovascular outcomes varied between the effective 141 
agents. 5-8 Liraglutide and semaglutide, with structural homology to native GLP-1, reduced 142 
cardiovascular events whereas there was no benefit with the exendin-4 based agents 143 
lixisenatide and exenatide.5-8 In addition to differences in chemical structure and potency, 144 
these treatments also differ markedly in duration of action and were studied in different 145 
patient populations and in trials of different design, size and duration of follow-up.5-8 146 
Consequently, there remains uncertainty about the cardiovascular effects of GLP-1 receptor 147 
agonists as a class. 148 
 149 
Albiglutide is a GLP-1 receptor agonist generated through genetic fusion of 2 tandem copies 150 
of modified human GLP-1 (97% amino acid sequence homology to endogenous human GLP-151 
1 fragment 7-36) to human albumin and is sufficiently long-acting to be injected weekly. 9,10   152 
In accordance with regulatory guidance, we assessed the cardiovascular safety and efficacy of 153 
albiglutide in Harmony Outcomes, a trial which included patients with type 2 diabetes and 154 
cardiovascular disease.11 155 
156 
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METHODS 157 
TRIAL OVERSIGHT 158 
We conducted this randomized, double-blind, placebo-controlled, event-driven trial at 610 159 
sites in 28 countries.11 The protocol was approved by the ethics committee at each 160 
participating site and all patients provided written informed consent. An independent data and 161 
safety monitoring committee, with access to unblinded data, performed regular safety 162 
surveillance.  163 
 164 
TRIAL POPULATION 165 
Men and women aged 40 years or older with a diagnosis of type 2 diabetes and established 166 
disease of the coronary (myocardial infarction, ≥50% stenosis in ≥1 coronary artery, or 167 
prior coronary revascularisation), cerebrovascular (ischaemic stroke, ≥50% carotid artery 168 
stenosis, or carotid vascular procedure), or peripheral arterial circulation (intermittent 169 
claudication and ankle:brachial index <0.9, non-traumatic amputation, or peripheral vascular 170 
procedure) who had a glycated haemoglobin level more than 7.0% (53 mmol per mole) were 171 
eligible for participation in the trial. 172 
Key exclusion criteria were estimated glomerular filtration rate [eGFR] less than 30 ml per 173 
minute per 1.73 m2 of body-surface area, severe gastroparesis, prior pancreatitis or significant 174 
risk factors for pancreatitis, a personal or family history of medullary carcinoma of the 175 
thyroid or multiple endocrine neoplasia type 2, history of pancreatic neuroendocrine tumour, 176 
or current use of a GLP-1 receptor agonist. A complete list of trial inclusion and exclusion 177 
criteria is provided in the protocol. 178 
Patients were assigned in a 1:1 ratio to receive subcutaneous injections of albiglutide or 179 
matching placebo once weekly, according to a sequestered, fixed, randomisation schedule. 180 
Investigators used an interactive voice or web response system to obtain treatment 181 
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assignment. The starting dose of study medication was 30 mg once weekly. If, after at least 5 182 
weeks of study treatment, the investigator determined that a trial participant required 183 
intensification of glucose-lowering therapy, the dose of study treatment could be increased to 184 
50 mg; the dose could be decreased back to 30 mg if 50 mg was not tolerated.  If the 185 
glycaemic goal determined by the investigator was not met following increase in dose of 186 
study medication, other glucose-lowering medications could be adjusted or added (except for 187 
a GLP-1-receptor agonist).  Protocol-specified reasons for discontinuation of trial medication 188 
included occurrence of pancreatitis, pancreatic cancer, medullary carcinoma of the thyroid or 189 
thyroid C-cell neoplasia, severe hypersensitivity reactions attributable to study medication, 190 
pregnancy, eGFR less than 15 ml per minute per 1.73 m2 of body-surface area, kidney 191 
dialysis or transplantation, or liver chemistry abnormalities exceeding protocol-specified 192 
thresholds.11 193 
 194 
OUTCOMES 195 
The primary outcome was defined as the first occurrence of any component of the composite 196 
outcome of death from cardiovascular causes, myocardial infarction, or stroke. Secondary 197 
cardiovascular outcomes included a four-component composite (the primary composite with 198 
the addition of urgent revascularisation for unstable angina), the individual components of the 199 
primary end point, and the composite of cardiovascular death or hospitalisation due to heart 200 
failure. Secondary metabolic end points included time to initiation of chronic insulin therapy, 201 
time to first occurrence of an important microvascular event, changes in glycated 202 
haemoglobin and weight, and proportion of participants achieving glycaemic control without 203 
severe hypoglycaemia and with a gain of less than 5% of body weight by the end of the 204 
study. Safety end points included change in blood pressure and heart rate, change in eGFR, 205 
and adverse events of special interest including, development of specified malignancies 206 
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(medullary thyroid cancer, pancreatic cancer and haematological malignancies), pancreatitis, 207 
severe hypoglycaemia, injection site reactions, immunological reactions, diabetic retinopathy, 208 
worsening renal function and death from any cause. A complete list of end points is included 209 
in the protocol. An independent clinical events classification committee whose members were 210 
unaware of the trial-group assignments adjudicated all the components of the primary 211 
composite outcome, secondary cardiovascular outcomes and death; these events are defined 212 
in the Clinical Event Definitions section in the Supplementary Appendix. A separate expert 213 
committee adjudicated suspected cases of pancreatitis. 214 
 215 
STATISTICAL ANALYSIS 216 
The primary objective of the trial was to investigate the effect of albiglutide, compared with 217 
placebo, on the primary outcome, testing first for noninferiority and, if the pre‐specified 218 
criterion for non‐inferiority was met, then for superiority. We used a closed testing procedure 219 
and therefore no adjustment of the significance level was required for testing of superiority.12 220 
Consistent with regulatory guidance, noninferiority would be declared if the upper limit of 221 
the two-sided 95% confidence interval of the hazard ratio was less than 1.30, and superiority 222 
established if the upper limit was less than 1.00.13, 14  223 
Assuming a true hazard of 1.00, we estimated that 611 events would be needed to have 90% 224 
power for the test of noninferiority. An event rate in the range of 2.0% to 3.0% per year was 225 
estimated for the primary end point, based on the results of prior trials, meaning that the 226 
target 611 events could be attained by following approximately 9400 patients for an average 227 
of 2.2 to 3.2 years. After the trial began, the blinded aggregate event rate was observed to be 228 
higher than anticipated, and, therefore, accrual of 611 events would occur over a much 229 
shorter period (potentially as short as a median of 1.1 years). To ensure adequate exposure for 230 
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evaluation of safety, the protocol was revised to require follow-up for a median of at least 1.5 231 
years in addition to the occurrence of at least 611 primary events. 232 
The time-to-event analyses of the primary and secondary cardiovascular outcomes were 233 
performed in the intention-to-treat population using Cox proportional hazards regression, 234 
with treatment group as the only explanatory variable.13 The Kaplan–Meier method was used 235 
to estimate event rates. These analyses included all patients randomly assigned to study 236 
treatment, whether taken or not, and followed to the study closure visit (or final date vital 237 
status could be ascertained). No adjustment for multiplicity was prespecified for the 238 
secondary and other endpoints and only 95% confidence intervals are provided.12  239 
The primary composite outcome was analysed in prespecified subgroups that were defined by 240 
baseline characteristics, including age at randomisation; sex; race/ethnicity; geographic 241 
region; type of glucose-lowering therapy (insulin, metformin and dipeptidyl peptidase-4 242 
inhibitor); duration of diabetes; history or no history of coronary artery disease, 243 
cerebrovascular disease, or peripheral arterial disease and combinations of these; history or 244 
no history of heart failure; use of statin or antiplatelet therapy; history of smoking; body-mass 245 
index; glycated haemoglobin level; eGFR.  246 
The safety analyses were performed in patients who underwent randomisation and received at 247 
least one dose of albiglutide or placebo. 248 
Baseline characteristics were summarised as means and standard deviations, medians and 249 
ranges, or percentages. Longitudinal measures, such as glycated haemoglobin level and body 250 
weight, were analysed using mixed model for repeated measurements, and the least-squares 251 
mean differences between treatment-groups were estimated, together with 95% confidence 252 
intervals. Analyses were performed using SAS software, version 9.4 (SAS Institute). 253 
 254 
Role of the funding source 255 
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The trial protocol was developed by the members of the Executive Committee in conjunction 256 
with Duke Clinical Research Institute and the sponsor, GlaxoSmithKline Research and 257 
Development Ltd. These parties were also responsible for oversight of trial. Details of the 258 
trial organisation and a complete list of the investigators are provided in the Supplementary 259 
Appendix. The statistical analyses were performed by a contract research organisation on 260 
behalf of the sponsor, according to a prespecified plan, and corroborated by Duke Clinical 261 
Research Institute. The statistical analysis plan is available in the Supplementary Appendix. 262 
All the authors had access to the final trial results and vouch for the accuracy and 263 
completeness of the data and analyses and for the fidelity of the trial to the protocol. The 264 
manuscript, drafted by the corresponding author, was revised and approved by all the authors, 265 
who assume responsibility for its accuracy and completeness and made the decision to submit 266 
the manuscript for publication. 267 
 268 
 269 
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 275 
 276 
 277 
 278 
 279 
 280 
13 
 
 281 
 282 
   283 
  284 
14 
 
RESULTS 285 
TRIAL CONDUCT 286 
A total of 9463 patients underwent randomisation between 1 July 2015 and 7 December 2016 287 
and were included in the intention-to-treat analysis; 4731 were assigned to receive albiglutide 288 
and 4732 to receive placebo. Starting 8 November 2017, when it was projected that 611 primary 289 
endpoints and a median follow-up of at least 1.5 years had accrued, subjects returned for a final 290 
visit and discontinuation from study treatment, with trial completion in March 2018. The actual 291 
median duration of follow-up was 1.6 years (interquartile range, 1.3 to 2.0; maximum, 2.6) for 292 
the primary outcome.  Vital status was not known for 61 of 9463 participants (0.6%) (Figure 293 
1).  A total of 24% of patients assigned to albiglutide and 27% of patients assigned to placebo 294 
discontinued study medication prematurely for reasons other than death.  Study treatment was 295 
taken for 87% of the total follow-up time for cardiovascular outcomes in the albiglutide group 296 
and 85% of that time in the placebo group. Among patients who received at least one dose of 297 
albiglutide or placebo, 2371 of 4717 patients (50.3%) in the albiglutide group were taking the 298 
maximum dose of 50 mg at the time of their last recorded dose, and 2982 of 4715 patients 299 
(63.2%) in the placebo group were taking the volume-matched equivalent. 300 
 301 
PATIENTS 302 
The demographic and clinical characteristics of the patients were similar in the two groups 303 
(Table 1). The mean age of the participants was 64.1 years and 30.6% were women. The mean 304 
duration of diabetes was 14.1 years, the mean eGFR was 79 ml per minute per 1.73 m2, and the 305 
mean glycated haemoglobin level was 8.7% (standard deviation, 1.5). 306 
Among the participants, 6678 (70.6%) had a history of coronary artery disease, 2354 (24.9%) 307 
peripheral artery disease, 2342 (24.7%) cerebrovascular disease and 1922 (20.3%) had a history 308 
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of heart failure. Patients received standard therapies for diabetes and cardiovascular disease 309 
(Table 1). 310 
PRIMARY AND SECONDARY OUTCOMES 311 
The primary composite endpoint occurred in 338 of 4731 patients (7.1%; 4.57 events per 100 312 
person-years) in the albiglutide group and in 428 of 4732 patients (9.0%; 5.87 events per 100 313 
person-years) in the placebo group (hazard ratio, 0.78; 95% CI, 0.68 to 0.90), indicating that 314 
albiglutide was both non-inferior to placebo for cardiovascular safety (P<0.001 for non-315 
inferiority) and superior to placebo for efficacy (P<0.001 for superiority) (Table 2 and Figure 316 
2).  The hazard ratios (95% confidence intervals) for each of the components of the composite 317 
were: death from cardiovascular causes 0.93 (0.73 – 1.19), myocardial infarction 0.75 (0.61 – 318 
0.90) and stroke 0.86 (0.66 – 1.14) (Table 2 and Figure 2).  Subgroup analyses are shown in 319 
Figure 3. Three of nineteen showed a nominally statistically significant interaction.  320 
The effects of albiglutide on the other secondary cardiovascular outcomes were consistent with 321 
its effect on the primary outcome (Table 2). The hazard ratio for death from any cause was 322 
0.95; 95% CI, 0.79 to 1.16. 323 
 324 
CHANGES IN METABOLIC MEASURES  325 
Mean glycated haemoglobin decreased more with albiglutide, compared with placebo 326 
(difference from placebo at 8 months -0.63, 95% CI -0.69 to -0.58; at 16 months -0.52, 95% 327 
CI -0.58 to -0.45) [Figure 4]. Body weight decreased more with albiglutide, compared with 328 
placebo (difference from placebo at 8 months –0.66, 95% CI, -0.83 to -0.49 kg; at 16 months 329 
–0.83, 95% CI, –1.06, –0.60). New treatment with insulin (taken for more than three months) 330 
was started in 107 patients (5.7%) in the albiglutide group and 257 patients (12.9%) in the 331 
placebo group (hazard ratio 0.42; 95% CI, 0.33 to 0.53, P<0.001). Other glucose lowering 332 
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therapies were added more often in the placebo group than in the albiglutide group 333 
(Supplementary Appendix). 334 
 335 
SAFETY 336 
Prespecified safety outcomes of special interest are shown in Table 3. The number of 337 
injection site reactions was greater in the albiglutide group than the placebo group (86 and 29 338 
patients, respectively), though the number of patients with suspected hypersensitivity 339 
reactions was similar in the two groups (45 and 48). Severe hypoglycaemia was less common 340 
in the albiglutide group than in the placebo group (31 and 55 patients). Other than for 341 
metabolism-related events which were less common in the albiglutide group, there were no 342 
clinically meaningful differences in serious adverse events between treatment groups 343 
(Supplementary Appendix). There was one lower-limb amputation in the albiglutide group 344 
and two in the placebo group. A total of 409 (8.6%) of patients assigned to albiglutide and 345 
307 (6.5%) of patients assigned to placebo discontinued study medication prematurely 346 
because of an adverse event. 347 
 348 
Mean systolic blood pressure decreased slightly more in albiglutide compared with placebo 349 
(difference at 8 months -0.65, 95% CI -1.27 to -0.03, and at 16 months -0.67, 95% CI -1.40 to 350 
0.06 mmHg) [Figure 4].  Heart rate increased more on albiglutide compared with placebo 351 
(difference at 8 months 1.3, 95% CI 0.9 to 1.6, and at 16 months 1.4, 95% CI 1.00 to 1.9 352 
beats per minute) [Supplementary Appendix].  The difference in eGFR between albiglutide 353 
and placebo at 8 months was -1.11, 95% CI -1.84 to -0.39 and at 16 months -0.43, 95% CI -354 
1.26 to +0.41 (Figure 4).   355 
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DISCUSSION 356 
In patients with type 2 diabetes and cardiovascular disease receiving standard care, addition 357 
of once-weekly albiglutide reduced the risk of the primary composite outcome - death from 358 
cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke – by 22%, compared 359 
with the addition of placebo. Overall, the number of patients who would need to be treated to 360 
prevent one event over a median of 1.6 years was 50.  361 
 All three components of the primary outcome, which were prespecified secondary outcomes, 362 
showed point estimates of an effect suggesting benefit, although only that for myocardial 363 
infarction was nominally statistically significant.  Comparing our findings to trials evaluating 364 
other GLP-1-receptor agonists, the effects observed were consistent with the benefits of 365 
liraglutide and semaglutide but appear greater than those of lixisenatide and exenatide.5-8 366 
Whether there are real differences among the findings of the trials conducted is uncertain. A 367 
number of factors including the specific molecule and dose tested, differences in the patients 368 
randomized, duration of follow-up, and adherence, could account for the apparent variation in 369 
results. However, this question can only be properly resolved by head-to-head comparisons 370 
between drugs and a recent meta-analysis showed only moderate heterogeneity between the 371 
between the prior trials which was not statistically significant. 5-8, 16, 17 372 
We did not see a statistically significant reduction in death from cardiovascular causes, as 373 
seen in the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome 374 
Results (LEADER). 5 However, we observed a delay between the initiation of treatment and 375 
the emergence of benefit, as was seen in earlier trials with GLP-1-receptor agonists, and the 376 
magnitude of the risk reduction for the primary outcome appeared to increase over time. 5-8 377 
The median follow-up in our trial was considerably shorter than the 3.8 years in LEADER 378 
and it may be that an effect on death from cardiovascular causes requires time to accrue.  379 
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The effect of albiglutide was consistent across most subgroups analysed, although three of the 380 
nineteen examined suggested some heterogeneity in the effect of treatment. Given the lack of 381 
a biologically plausible explanation for this, and the absence of similar interactions in other 382 
trials using GLP-1-recpetor agonists, we believe that our findings probably reflect the play of 383 
chance, related to the large number of subgroups analysed.  384 
The point estimate for another secondary outcome, death from cardiovascular causes or heart 385 
failure hospitalisation, also favoured albiglutide but was not statistically significant. This is 386 
clinically relevant, given concerns about increased risk of heart failure with certain other 387 
glucose-lowering therapies18.  388 
The benefit of albiglutide was evident in patients who were well treated with other effective 389 
cardiovascular therapies. Despite no major difference between randomised treatment groups 390 
in blood pressure, body weight, or renal function over time, treatment with albiglutide 391 
reduced the risk of major cardiovascular events over a relatively short period of follow-up. 392 
The mean glycated haemoglobin level at baseline was 8.7% and was reduced by 393 
approximately 1% at four months in the albiglutide group, compared with placebo, and 394 
remained lower in the albiglutide group for the duration of the trial, despite a decrease over 395 
time in glycated haemoglobin in the placebo group. Other glucose-lowering therapies, 396 
including SGLT2 inhibitors and insulin, were added more commonly in patients the placebo 397 
group, compared with the albiglutide group. The exact reasons why GLP-1 receptor agonists 398 
reduce athero-thrombotic events is unknown but putative, potentially beneficial, 399 
cardiovascular actions have been described.19 400 
The only prespecified adverse event of interest that was significantly more common in the 401 
albiglutide group was injection-site reaction, although this occurred in less than two percent 402 
of patients. Severe hypoglycaemia was uncommon overall and occurred less frequently in the 403 
albiglutide group than in the placebo group, probably due, in part, to the greater use of insulin 404 
19 
 
and other glucose-lowering therapies in the placebo group. There was no excess of reported 405 
new or worsening retinopathy in the albiglutide group.20, 21  Only serious adverse events were 406 
collected in addition to the prespecified adverse events of interest and these did not show any 407 
difference between albiglutide and placebo for non-metabolism-related events. Overall, 408 
albiglutide was discontinued slightly less frequently than placebo, although it should be noted 409 
that, by design, our trial did not require forced up-titration of the dose of study drug. 11  410 
One strength of our trial was that, except for GLP-1-receptor agonists, investigators were free 411 
to use any other glucose-lowering therapy, including dipeptidyl peptidase 4 inhibitors and 412 
SGLT2 inhibitors. The inclusion and exclusion criteria ensured a high rate of cardiovascular 413 
events. Our trial also has some limitations, including the relatively short duration of follow-414 
up, and lack of measurement of lipids and urinary albumin excretion. We did not collect 415 
detailed information on microvascular complications. Although the short overall duration of 416 
follow-up might raise concerns about identification of longer-term safety problems, prior 417 
studies with albiglutide collected information on safety and tolerability for up to 3 years. 418 
About one quarter of patients discontinued study treatment but this appears in line with 419 
discontinuation rates in other trials using GLP-1-receptor agonists and study treatment was 420 
taken for approximately 86% of total follow-up time for cardiovascular outcomes 421 
In summary, when added to standard care in patients with type 2 diabetes and established 422 
cardiovascular disease, the long-acting GLP-1-receptor agonist albiglutide reduced the risk of 423 
major adverse cardiovascular events with acceptable tolerability and safety. These findings 424 
provide more evidence that certain GLP-1-receptor agonists can improve cardiovascular 425 
outcomes in patients with type 2 diabetes. 21-23 426 
 427 
 428 
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Table Legends 576 
Table 1.  Characteristics of the Patients at Baseline. 577 
 578 
Table 2. Primary and Secondary Cardiovascular Outcomes. 579 
 580 
Table 3. Adverse Events of Special Interest. 581 
 582 
Figure Legends 583 
Figure 1. Enrollment, Follow-up, and Vital Status 584 
ITT = intention-to-treat MACE = major adverse cardiovascular events  585 
Figure 2. Cardiovascular Outcomes  586 
The primary outcome was a composite of death from cardiovascular causes, myocardial 587 
infarction, or stroke. The cumulative incidences of the primary outcome and its components 588 
were estimated with the use of the Kaplan–Meier method and hazard ratios and 95% confidence 589 
intervals were estimated with the use of Cox regression models, with treatment with albiglutide 590 
or placebo as the sole explanatory variable. Analyses are based upon all participants who 591 
underwent randomisation. The displays are truncated at the point where less than 10% of 592 
patients remains at risk. The inset in each panel shows the same data on an enlarged y axis. 593 
Figure 3. Primary Composite Outcome According to Prespecified Subgroups. 594 
Race or ethnic group was reported by the patient. The body-mass index (BMI) is the weight in 595 
kilograms divided by the square of the height in meters. Cerebrovascular disease included any 596 
of stroke, ≥50% carotid artery stenosis or carotid arterial procedure. DPP-4 denotes dipeptidyl 597 
peptidase 4, and GFR glomerular filtration rate. HbA1c = glycated haemoglobin. P values for 598 
homogeneity for between-group differences were obtained by fitting interaction terms, with no 599 
adjustment for multiple testing. 600 
Figure 4. Effects of once-weekly albiglutide 601 
Shown are the effects of once-weekly administration of albiglutide on glycated haemoglobin 602 
levels, body weight, systolic blood pressure, and estimated glomerular filtration rate. Overall 603 
least-squares mean differences were estimated from the model that included only the patients 604 
in whom a baseline value and at least one postbaseline value were obtained.  605 
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Table 1.  Characteristics of the Patients at Baseline. 606 
 607 
 
Albiglutide (N=4731) Placebo (N=4732) 
 
Age -yr 64.1 ± 8.7 64.2 ± 8.7 
Female sex – no. (%) 1427 (30.2) 1467 (31.0) 
Race/ethnicity (%) 
  
Non-Hispanic White 3295 (69.7) 3288 (69.5) 
Asian 228 (4.8) 242 (5.1) 
Non-Hispanic Black or African-American 111 (2.4) 114 (2.4) 
Hispanic 1005 (21.2) 988 (20.9) 
Other 92 (1.9) 100 (2.1) 
Geographic region – no. (%) 
  
Western Europe 1684 (35.6) 1708 (36.1) 
Eastern/Central Europe 1037 (21.9) 1010 (21.3) 
North America 967 (20.4) 978 (20.7) 
Latin America 858 (18.1) 845 (17.9) 
Asia Pacific 185 (3.9) 191 (4.0) 
Current smoking – no. (%) 737 (15.6) 751 (15.9) 
Medical history – no. (%)   
Coronary artery disease# 3333 (70.5%) 3345 (70.7%) 
Hypertension 4089 (86.4) 4095 (86.5) 
Myocardial infarction 2223 (47.0) 2236 (47.3) 
Coronary artery bypass surgery 890 (18.8) 842 (17.8) 
Percutaneous coronary intervention 2050 (43.3%) 2113 (44.7%) 
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Stroke 827 (17.5) 854 (18.0) 
Peripheral artery disease 1195 (25.3) 1159 (24.5) 
Heart failure 954 (20.2) 968 (20.5) 
Atrial fibrillation 394 (8.3%) 392 (8.3%) 
Body-mass index – kg/m2 32.3 ± 5.9 32.3 ± 5.9 
Blood pressure - mmHg   
Systolic 134.8 ± 16.6 134.7 ± 16.5 
Diastolic 76.8 ± 10.1 76.8 ± 10.1 
Glycated haemoglobin - % 8.76 ± 1.5 8.72 ± 1.5 
eGFR - ml/min/1.73m2 79.1 ± 25.6 78.9 ± 25.4 
Duration of diabetes - yr 14.1 ± 8.6 14.2 ± 8.9 
History of microvascular disease – no. (%)   
Diabetic eye disease 982 (20.8) 955 (20.2) 
Nephropathy 898 (19.0) 840 (17.8) 
Peripheral Sensory Neuropathy 1562 (33.0) 1533 (32.4) 
Autonomic Neuropathy 143 (3.0) 107 (2.3) 
Cardiovascular medications – no. (%)   
Beta-blocker 3128 (66.1) 3182 (67.2) 
Calcium-channel blocker 1428 (30.2) 1431 (30.2) 
ACE inhibitor 2263 (47.8) 2353 (49.7) 
Angiotensin receptor blocker 1599 (33.8) 1511 (31.9) 
Thiazide diuretic 1089 (23.0) 1037 (21.9) 
Loop diuretic 895 (18.9) 899 (19.0) 
Statin 3967 (83.9) 3988 (84.3) 
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Aspirin 3652 (77.2) 3639 (76.9) 
P2Y12 inhibitor 1224 (25.9) 1251 (26.4) 
Glucose-lowering medications – no. (%)   
None/diet 42 (0.9) 35 (0.7) 
Biguanide 3463 (73.2) 3506 (74.1) 
Sulfonylurea 1346 (28.5) 1379 (29.1) 
Insulin 2860 (60.5) 2737 (57.8) 
DPP-4 inhibitor 698 (14.8) 739 (15.6) 
SGLT-2 inhibitor 310 (6.6) 265 (5.6) 
Thiazolidinedione 92 (1.9) 102 (2.2) 
Glinide 66 (1.4) 96 (2.0) 
-Glucosidase inhibitor 34 (0.7) 37 (0.8) 
 608 
# Any of myocardial infarction, coronary artery bypass grafting, percutaneous coronary 609 
intervention or ≥50% stenosis of coronary artery on angiography  610 
Plus-minus values are means ± SD  611 
ACE denotes angiotensin-converting enzyme 612 
SGLT-2 denotes sodium-glucose cotransporter 2 613 
DPP-4 denotes dipeptidyl peptidase 4614 
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Table 2. Primary and Secondary Cardiovascular Outcomes* 615 
 616 
Outcome Albiglutide 
(N=4731) 
Incidence 
Rate 
Placebo 
(N=4732) 
Incidence 
Rate 
Hazard Ratio 
(95% CI) 
P Value 
Noninferiority 
Superiority 
 
no. of patients 
(%) 
no. of events/ 
100 patient-yr 
no. of patients 
(%) 
no. of events/ 
100 patient-yr 
  
Primary composite outcome† 338 (7.1) 4.57 428 (9.0) 5.87 0.78  
(0.68 – 0.90) 
<0.0001 
=0.0006 
Secondary outcomes       Superiority 
(nominal) 
Expanded composite†† 373 (7.9) 5.06 468 (9.9) 6.45 0.78  
(0.69 – 0.90) 
<0.001 
Death from cardiovascular 
causes 
122 (2.6) 1.61 130 (2.7) 1.72 0.93  
(0.73 – 1.19) 
0.578 
Fatal or nonfatal myocardial 
infarction 
181 (3.8) 2.43 240 (5.1) 3.26 0.75  
(0.61 – 0.90) 
0.003 
Fatal or nonfatal stroke 94 (2.0) 1.25 108 (2.3) 1.45 0.86  0.300 
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(0.66 – 1.14) 
Death from cardiovascular 
causes or hospitalisation for 
heart failure  
188 (4.0) 2.49 218 (4.6) 2.92 0.85  
(0.70 – 1.04) 
0.113 
Death from any cause 196 (4.1) 2.44 205 (4.3) 2.56 0.95  
(0.79 – 1.16) 
0.644 
 617 
* Hazard ratios and P vales were estimated using a Cox proportional-hazards model with treatment as the sole explanatory variable 618 
† The primary composite outcome in the time-to-event analysis consisted of the first occurrence of death from cardiovascular causes (102 619 
patients in the albiglutide group vs. 109 in the placebo group), nonfatal myocardial infarction (160 vs. 228) or nonfatal stroke (76 vs. 91).  The P 620 
value is for superiority. 621 
†† The expanded composite outcome included death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke or urgent 622 
coronary revascularization for unstable angina.623 
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Table 3. Prespecified Adverse Events of Special Interest.+ 624 
 Albiglutide 
(n=4717)* 
Placebo 
(n=4715)* 
 
 n (%) n (%) RR (95% CI) 
Severe hypoglycemia 31 (0.7) 55 (1.2) 0.56 (0.36-0.87) 
Pancreatitis† 10 (0.2) 7 (0.1) 1.43 (0.54-3.75) 
Injection site reactions 86 (1.8) 29 (0.6) 2.96 (1.95-4.51) 
Thyroid cancer 0 (0) 0 (0) - 
Hematologic neoplasia 9 (0.2) 5 (0.1) 1.80 (0.60-5.36) 
Pancreatic cancer  6 (0.1) 5 (0.1) 1.20 (0.37-3.93) 
Hypersensitivity Syndrome/Symptoms 45 (1.0) 48 (1.0) 0.94 (0.63-1.40) 
Hepatobiliary disorders 51 (1.1) 41 (0.9) 1.24 (0.83-1.87) 
Alanine aminotransferase ≥3xULN ‡ 17 (0.4) 30 (0.6) 0.57 (0.31-1.03) 
Alanine aminotransferase ≥5x ULN ‡ 6 (0.1) 17 (0.4) 0.35 (0.14-0.89) 
Bilirubin ≥2x ULN ‡ 12 (0.3) 7 (0.1) 1.71 (0.68-4.35) 
Serious gastrointestinal events 92 (2.0) 87 (1.8) 1.06 (0.79-1.41) 
Appendicitis 3 (<0.1) 8 (0.2) 0.37 (0.10-1.41) 
Atrial fibrillation/flutter 108 (2.3) 131 (2.8) 0.82 (0.64-1.06) 
Pneumonia 131 (2.8) 138 (2.9) 0.95 (0.75-1.20) 
Renal Impairment** 279 (5.9) 319 (6.8) 0.87 (0.75-1.02) 
Diabetic retinopathy 78 (1.7) 89 (1.9) 0.88 (0.65-1.18) 
 625 
+Definitions/details in Supplementary Appendix *In patients who took at least one dose. 626 
RR=relative risk  627 
† Events prospectively adjudicated to be definite or possible pancreatitis by treatment-blind 628 
adjudication committee  629 
‡ ULN = Upper limit of normal. Hepatic enzyme elevation was pre-defined as an Adverse Event of 630 
Special Interest. There were 4 cases where the alanine aminotransferase ≥3xULN and bilirubin 631 
≥2x ULN: 1 in the albiglutide group, 3 in the placebo group. 632 
** Acute kidney injury was reported by investigators in 70 patients in the albiglutide group and in 633 
80 in the placebo group. 634 
 635 
